Impact of Aflibercept Dosing Frequency on Retinal Nonperfusion Progression Assessed by Ultra-Widefield Angiography After Endolaserless Vitrectomy for Proliferative Diabetic Retinopathy–Related Vitreous Hemorrhage
Restricted accessResearch articleFirst published online 2026
Impact of Aflibercept Dosing Frequency on Retinal Nonperfusion Progression Assessed by Ultra-Widefield Angiography After Endolaserless Vitrectomy for Proliferative Diabetic Retinopathy–Related Vitreous Hemorrhage
Purpose: To investigate the effect of intravitreal (IVT) aflibercept injection monotherapy on retinal ischemia in eyes with severe proliferative diabetic retinopathy (PDR) that underwent pars plana vitrectomy (PPV) without panretinal photocoagulation (PRP) for vitreous hemorrhage. Methods: Thirty-one eyes with PDR-related vitreous hemorrhage underwent PPV without endolaser PRP and received 1 preoperative and 1 intraoperative IVT aflibercept injection before being randomized postoperatively to receive an IVT aflibercept injection once every 8 weeks (q8-week) or once every 16 weeks (q16-week). Ultra-widefield fluorescein angiography (FA) was performed 4 weeks post-PPV (baseline) and quarterly for 3 years. Images were independently graded at the Wisconsin Reading Center for the nonperfusion index, which is the proportion of assessable retinal area demonstrating capillary nonperfusion on ultra-widefield FA. Results: The IVT aflibercept q16-week group showed a significant increase in nonperfusion index of 0.096 by week 152 (P < .0001), whereas the q8-week group showed no significant progression. The q8-week group received more total injections and reached therapeutic saturation earlier, whereas the q16-week group showed a significant increase in unscheduled rescue injections across successive intervals (weeks 52-104, P = .017; weeks 104-152, P = .045) and still demonstrated worsening ischemia. In the q16-week group, higher cumulative injection counts correlated positively with nonperfusion index burden (P = .016), a relationship not observed in the q8-week group (P = .82). Conclusions: In eyes with PDR that underwent PPV without PRP, more frequent aflibercept dosing (q8-week) mitigated progression of retinal nonperfusion compared with extended-interval (q16-week) aflibercept therapy, suggesting that tighter antivascular endothelial growth factor treatment intervals may slow retinal ischemic progression.
ShahGNMorofujiYBanksWAPriceTO.High glucose-induced mitochondrial respiration and reactive oxygen species in mouse cerebral pericytes is reversed by pharmacological inhibition of mitochondrial carbonic anhydrases: implications for cerebral microvascular disease in diabetes. Biochem Biophys Res Commun. 2013;440(2):354-358. doi:10.1016/j.bbrc.2013.09.086
2.
RaHParkJHBaekJUBaekJ.Relationships among retinal nonperfusion, neovascularization, and vascular endothelial growth factor levels in quiescent proliferative diabetic retinopathy. J Clin Med. 2020;9(5):1462. doi:10.3390/jcm9051462
3.
JungEELinMRyuC, et al. Association of the pattern of retinal capillary non-perfusion and vascular leakage with retinal neovascularization in proliferative diabetic retinopathy. J Curr Ophthalmol. 2021;33(1):56-61. doi:10.4103/JOCO.JOCO_234_20
4.
MarcusDMSilvaPSLiuD, et al. Association of predominantly peripheral lesions on ultra-widefield imaging and the risk of diabetic retinopathy worsening over time. JAMA Ophthalmol. 2022;140(10):946-954. doi:10.1001/jamaophthalmol.2022.3131
5.
SilvaPSMarcusDMLiuD, et al. Association of ultra-widefield fluorescein angiography-identified retinal nonperfusion and the risk of diabetic retinopathy worsening over time. JAMA Ophthalmol. 2022;140(10):936-945. doi:10.1001/jamaophthalmol.2022.3130
6.
SilvaPSDela CruzAJLedesmaMG, et al. Diabetic retinopathy severity and peripheral lesions are associated with nonperfusion on ultrawide field angiography. Ophthalmology. 2015;122(12):2465-2472. doi:10.1016/j.ophtha.2015.07.034
7.
WykoffCCYuHJAveryRL, et al. Retinal non-perfusion in diabetic retinopathy. Eye (Lond). 2022;36(2):249-256. doi:10.1038/s41433-021-01649-0
8.
HwangTSGaoSSLiuL, et al. Automated quantification of capillary nonperfusion using optical coherence tomography angiography in diabetic retinopathy. JAMA Ophthalmol. 2016;134(4):367-373. doi:10.1001/jamaophthalmol.2015.5658
9.
NesperPLRobertsPKOnishiAC, et al. Quantifying microvascular abnormalities with increasing severity of diabetic retinopathy using optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2017;58(6):BIO307-BIO315. doi:10.1167/iovs.17-21787
10.
BrownDMNguyenQDMarcusDM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022. doi:10.1016/j.ophtha.2013.02.034
11.
WellsJAGlassmanARAyalaAR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351-1359. doi:10.1016/j.ophtha.2016.02.022
12.
WykoffCCAbreuFAdamisAP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741-755. doi:10.1016/S0140-6736(22)00018-6
13.
BrownDMBoyerDSDoDV, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024;403(10432):1153-1163. doi:10.1016/S0140-6736(23)02577-1
14.
SunJKGlassmanARBeaulieuWT, et al. Rationale and application of the Protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy. Ophthalmology. 2019;126(1):87-95. doi:10.1016/j.ophtha.2018.08.001
15.
BrownDMWykoffCCBoyerD, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial. JAMA Ophthalmol. 2021;139(9):946-955. doi:10.1001/jamaophthalmol.2021.2809
16.
MaturiRKGlassmanARJosicK, et al. Four-year visual outcomes in the protocol W randomized trial of intravitreous aflibercept for prevention of vision-threatening complications of diabetic retinopathy. JAMA. 2023;329(5):376-385. doi:10.1001/jama.2022.25029
17.
ChatziralliITouhamiSCicinelliMV, et al. Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy. Eye (Lond). 2022;36(4):692-703. doi:10.1038/s41433-021-01750-4
18.
NanjiKSarohiaGSXieJ, et al. Anti-vascular endothelial growth factor therapy and retinal non-perfusion in diabetic retinopathy: a meta-analysis of randomised trials. Acta Ophthalmol. 2024;102(1):e31-e41. doi:10.1111/aos.15673
19.
KimKKimESYuS-Y.Longitudinal changes in retinal microvasculature after panretinal photocoagulation in diabetic retinopathy using swept-source OCT angiography. Sci Rep. 2021;11(1):216. doi:10.1038/s41598-020-80697-0
20.
LevinAMRusuIOrlinA, et al. Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections. Clin Ophthalmol. 2017;11:193-200. doi:10.2147/OPTH.S118807
21.
TakahashiKKishiSMuraokaKShimizuK.Reperfusion of occluded capillary beds in diabetic retinopathy. Am J Ophthalmol. 1998;126(6):791-797. doi:10.1016/s0002-9394(98)00242-6
22.
WykoffCCNittalaMGVillanueva BooneC, et al. Final outcomes from the randomized RECOVERY trial of aflibercept for retinal nonperfusion in proliferative diabetic retinopathy. Ophthalmol Retina. 2022;6(7):557-566. doi:10.1016/j.oret.2022.02.013
23.
ShirakiATsuboiKWakabayashiTShirakiNNishidaK.Reperfusion of retinal nonperfusion by neovascular-vascular anastomosis in proliferative diabetic retinopathy. Eur J Ophthalmol. 2024;34(2):NP28-NP32. doi:10.1177/11206721231210896
24.
OmaeTNagaokaTYoshidaA.Retinal reperfusion following panretinal photocoagulation for diabetic retinopathy. Invest Ophthalmol Vis Sci. 2014;55(13):3899-3899.
25.
NeubauerASKookDHaritoglouC, et al. Bevacizumab and retinal ischemia. Ophthalmology. 2007;114(11):2096-2096.e2. doi:10.1016/j.ophtha.2007.05.057
26.
FilekRHooperPSheidowTGGonderJChakrabartiSHutnikCM.Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients. Clin Ophthalmol. 2019;13:1087-1096. doi:10.2147/OPTH.S199758
27.
KimYJYeoJHSonG, et al. Efficacy of intravitreal AFlibercept injection For Improvement of retinal Nonperfusion In diabeTic retinopathY (AFFINITY study). BMJ Open Diabetes Res Care. 2020;8(1):e001616. doi:10.1136/bmjdrc-2020-001616
28.
HeierJSKorobelnikJFBrownDM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376-2385. doi:10.1016/j.ophtha.2016.07.032
29.
SivaprasadSPrevostATVasconcelosJC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389(10085):2193-2203. doi:10.1016/S0140-6736(17)31193-5
30.
ErolNGursoyHKimyonSTopbasSColakE.Vision, retinal thickness, and foveal avascular zone size after intravitreal bevacizumab for diabetic macular edema. Adv Ther. 2012;29(4):359-369. doi:10.1007/s12325-012-0009-9
31.
FeuchtNSchönbachEMLanzlIKotliarKLohmannCPMaierM.Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease. Clin Ophthalmol. 2013;7:173-178. doi:10.2147/OPTH.S37544
32.
NakamuraSTsurumaKShimazawaMHaraH.Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression. Eur J Pharmacol. 2012;685(1-3):8-14. doi:10.1016/j.ejphar.2012.04.017
33.
RuiaSTripathyK.Fluorescein angiography. In: StatPearls [Internet]. StatPearls Publishing; 2024 Jan-. Updated August 25, 2023. Accessed February 1, 2024. https://www.ncbi.nlm.nih.gov/books/NBK576378/
34.
WykoffCCNittalaMGZhouB, et al. Intravitreal aflibercept for retinal nonperfusion in proliferative diabetic retinopathy: outcomes from the randomized RECOVERY trial. Ophthalmol Retina. 2019;3(12):1076-1086. doi:10.1016/j.oret.2019.07.011
35.
NicholsonLCrosby-NwaobiRVasconcelosJC, et al. Mechanistic evaluation of panretinal photocoagulation versus aflibercept in proliferative diabetic retinopathy: CLARITY substudy. Invest Ophthalmol Vis Sci. 2018;59(10):4277-4284. doi:10.1167/iovs.17-23509
36.
NguyenQDBrownDMMarcusDM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801. doi:10.1016/j.ophtha.2011.12.039
37.
RajendramRFraser-BellSKainesA, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972-979. doi:10.1001/archophthalmol.2012.393
38.
ComynOSivaprasadSPetoT, et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol. 2014;157(5):960-970. doi:10.1016/j.ajo.2014.02.019
39.
BrownDMOuWCWongTP, et al. Targeted retinal photocoagulation for diabetic macular edema with peripheral retinal nonperfusion: three-year randomized DAVE trial. Ophthalmology. 2018;125(5):683-690. doi:10.1016/j.ophtha.2017.11.026
40.
KasettyVMStarnesDCSoodN, et al. Complications, compliance, and 3-year outcomes after endolaserless vitrectomy with aflibercept monotherapy for proliferative diabetic retinopathy-related vitreous hemorrhage. Ophthalmic Surg Lasers Imaging Retina. 2023;54(2):89-96. doi:10.3928/23258160-20221216-02
41.
MarcusDMStarnesDWaliaH, et al. Endolaserless vitrectomy with aflibercept for proliferative diabetic retinopathy-related vitreous hemorrhage (LASER LESS TRIAL): 1-year results. J Clin Ophthalmol. 2020;4(2):254-265.
42.
MarcusDMSinghHStarnesDC, et al. Endolaserless vitrectomy with intravitreal aflibercept injection for proliferative diabetic retinopathy-related vitreous hemorrhage (LASER LESS TRIAL). J Vitreoretin Dis. 2018;2(3):127-137. doi:10.1177/2474126418764972
43.
MoritaAGokoTMatsumuraM, et al. The process of revascularization in the neonatal mouse retina following short-term blockade of vascular endothelial growth factor receptors. Cell Tissue Res. 2020;382(3):529-549. doi:10.1007/s00441-020-03276-9
44.
FanWWangKGhasemi FalavarjaniK, et al. Distribution of nonperfusion area on ultra-widefield fluorescein angiography in eyes with diabetic macular edema: DAVE study. Am J Ophthalmol. 2017;180:110-116. doi:10.1016/j.ajo.2017.05.024
45.
WykoffCCShahCDhootD, et al. Longitudinal retinal perfusion status in eyes with diabetic macular edema receiving intravitreal aflibercept or laser in VISTA study. Ophthalmology. 2019;126(8):1171-1180. doi:10.1016/j.ophtha.2019.03.040
46.
ReddyRKPieramiciDJGuneS, et al. Efficacy of ranibizumab in eyes with diabetic macular edema and macular nonperfusion in RIDE and RISE. Ophthalmology. 2018;125(10):1568-1574. doi:10.1016/j.ophtha.2018.04.002
47.
KarstSGDeakGGGerendasBS, et al. Association of changes in macular perfusion with ranibizumab treatment for diabetic macular edema: a subanalysis of the RESTORE (extension) study. JAMA Ophthalmol. 2018;136(4):315-321. doi:10.1001/jamaophthalmol.2017.6135
48.
CouturierAReyPAErginayA, et al. Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor. Ophthalmology. 2019;126(12):1685-1694. doi:10.1016/j.ophtha.2019.06.022
49.
BonninSDupasBLaviaC, et al. Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinal perfusion. Retina. 2019;39(3):426-434. doi:10.1097/IAE.0000000000002422
50.
FigueiredoNSrivastavaSKSinghRP, et al. Longitudinal panretinal leakage and ischemic indices in retinal vascular disease after aflibercept therapy: the PERMEATE study. Ophthalmol Retina. 2020;4(2):154-163. doi:10.1016/j.oret.2019.09.001
51.
MorelJBFajnkuchenFAmariFSritharanNBloch-QueyratCGiocanti-AuréganA.Ultra-wide-field fluorescein angiography assessment of non-perfusion in patients with diabetic retinopathy treated with anti-vascular endothelial growth factor therapy. J Clin Med. 2023;12(4):1365. doi:10.3390/jcm12041365
52.
HolekampNMShuiYBBeebeDC.Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation. Am J Ophthalmol. 2005;139(2):302-310. doi:10.1016/j.ajo.2004.09.046
53.
HolekampNMShuiYBBeebeD.Lower intraocular oxygen tension in diabetic patients: possible contribution to decreased incidence of nuclear sclerotic cataract. Am J Ophthalmol. 2006;141(6):1027-1032. doi:10.1016/j.ajo.2006.01.016
54.
LederHAJabsDAGalorADunnJPThorneJE.Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol. 2011;152(3):441-448.e2. doi:10.1016/j.ajo.2011.02.009
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
